Abstract
Both clinical and biological features have been reported as prognostic factors in low-grade gliomas. Among these, histotype, tumor size, enhancement, age and genetic pattern. Microvessel density (MVD) has been correlated to clinical outcome in astrocytomas, but its impact in oligodendrogliomas and mixed tumors is not sure. The pro-angiogenic chemokine stromal cell-derived factor (SDF-1/CXCL12) and its receptor CXC chemokine receptor 4 (CXCR4) have been described in low-grade gliomas, with a correlation between CXCL12 expression and shorter time to progression (TTP). The intermediate filament Nestin is expressed in proliferating vessels. Platelet-derived growth factor B (PDGF-B) and its receptor PDGFR-beta are also involved in angiogenesis and malignant progression in gliomas.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Astrocytoma / blood supply*
-
Astrocytoma / diagnosis*
-
Astrocytoma / pathology
-
Brain Neoplasms / blood supply*
-
Brain Neoplasms / diagnosis*
-
Brain Neoplasms / pathology
-
Capillaries / pathology
-
Chemokine CXCL12
-
Chemokines, CXC / analysis*
-
Female
-
Humans
-
Intermediate Filament Proteins / analysis
-
Male
-
Middle Aged
-
Neovascularization, Pathologic / diagnosis*
-
Neovascularization, Pathologic / pathology
-
Nerve Tissue Proteins / analysis
-
Nestin
-
Oligodendroglioma / blood supply*
-
Oligodendroglioma / diagnosis*
-
Oligodendroglioma / pathology
-
Prognosis
-
Proto-Oncogene Proteins c-sis / analysis
-
Receptor, Platelet-Derived Growth Factor beta / analysis
-
Receptors, CXCR4 / analysis
Substances
-
CXCL12 protein, human
-
Chemokine CXCL12
-
Chemokines, CXC
-
Intermediate Filament Proteins
-
NES protein, human
-
Nerve Tissue Proteins
-
Nestin
-
Proto-Oncogene Proteins c-sis
-
Receptors, CXCR4
-
Receptor, Platelet-Derived Growth Factor beta